Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT04777994 · ClinicalTrials.gov registry record · Phase 1
Study With ABBV-CLS-484 in Participants With Locally Advanced or Metastatic Tumors
A Phase 1 study of Advanced Solid Tumor Cancer, sponsored by Calico Life Sciences.
- Recruiting
- Registry status
- Phase 1
- Development phase
- 248
- Enrollment target
- 20
- Study locations
NCT04777994 is a Phase 1 study of Advanced Solid Tumor Cancer that is actively recruiting participants, run by Calico Life Sciences. The registered enrollment target is 248 participants. The trial reports 20 study locations across 15 states.
The verdict
NCT04777994, a Phase 1 study of Advanced Solid Tumor Cancer, is actively recruiting participants, sponsored by Calico Life Sciences.
- RECRUITING
- Registry status
- Phase 1
- Development phase
- 248 participants
- Enrollment target
- 20
- Study locations
Study Summary
The study will assess the safety, PK, PD, and preliminary efficacy of ABBVCLS-484 as monotherapy and in combination with a PD-1 targeting agent or with a or a vascular endothelial growth factor receptor (VEGFR) tyrosine kinase inhibitor (TKI). The trial aims to establish a safe, tolerable, and efficacious dose of ABBVCLS-484 as monotherapy and in combination. The study will be conducted in three parts. Part 1 Monotherapy Dose Escalation, Part 2 Combination Dose Escalation and Part 3 Dose Expansion (Monotherapy and Combination therapy). Part 1, ABBV-CLS-484 will be administered alone in escalating dose levels to eligible subjects who have advanced solid tumors. Part 2, ABBV-CLS-484 will be administered at escalating dose levels in combination with a PD-1 targeting agent or with a VEGFR TKI to eligible subjects who have advanced solid tumors. Part 3, ABBV-CLS-484 will be administered alone as a monotherapy at the determined recommended dose in subjects with locally advanced or metastatic, relapsed or refractory head and neck squamous cell carcinoma (HNSCC), relapsed or refractory non-small cell lung cancer (NSCLC), and advanced clear cell renal cell carcinoma (ccRCC). ABBV-CLS-484 will also be administered at the determined recommended dose in combination with a PD-1 targeting or with a VEGFR TKI agent in subjects with locally advanced or metastatic, HNSCC, NSCLC, MSI-H tumors refractory to PD-1/PD-L1, and advanced ccRCC.
Conditions Studied
Interventions
- DRUG ABBV-CLS-484
- DRUG Vascular Endothelial Growth Factor Receptor (VEGFR) Tyrosine Kinase Inhibitor (TKI)
- DRUG Programmed Cell Death-1 (PD-1) Inhibitor
Study Locations (20)
Texas
- University of Texas Southwestern Medical Center /ID# 251974 - Dallas
- University of Texas MD Anderson Cancer Center /ID# 252004 - Houston
- NEXT Oncology /ID# 225708 - San Antonio
Massachusetts
- Beth Israel Deaconess Medical Center /ID# 252009 - Boston
- Dana-Farber Cancer Institute /ID# 249642 - Boston
North Carolina
- Duke Cancer Center /ID# 251975 - Durham
- Carolina BioOncology Institute /ID# 225704 - Huntersville
Pennsylvania
- Perelman Center for Advanced Medicine /ID# 250188 - Philadelphia
- UPMC Hillman Cancer Ctr /ID# 225706 - Pittsburgh
Arizona
- University of Arizona Cancer Center - Tucson /ID# 262698 - Tucson
Connecticut
- Yale University School of Medicine /ID# 225707 - New Haven
Maryland
- Johns Hopkins Hospital /ID# 254056 - Baltimore
Michigan
- University of Michigan Comprehensive Cancer Center Michigan Medicine /ID# 252010 - Ann Arbor
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 248 participants |
| Start Date | 2021-03-09 |
| Est. Completion | 2026-10 |
| Phase | Phase 1 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT04777994
The ClinicalTrials.gov registry entry for NCT04777994 describes a study currently listed as recruiting, categorized as Phase 1. The registered enrollment target is 248 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Calico Life Sciences, which has 6 total studies on file at ClinicalTrials.gov.
The record links to 1 condition, with Advanced Solid Tumor Cancer appearing as the primary indexed condition, and to 3 interventions - of which ABBV-CLS-484 is the first listed.
NCT04777994 reports 20 study locations spanning 15 distinct geographic areas - top geographies include Texas, Massachusetts, North Carolina.
Frequently Asked Questions
What is clinical trial NCT04777994 about?
NCT04777994 is a clinical study titled "Study With ABBV-CLS-484 in Participants With Locally Advanced or Metastatic Tumors". The study will assess the safety, PK, PD, and preliminary efficacy of ABBVCLS-484 as monotherapy and in combination with a PD-1 targeting agent or with a or a vascular endothelial growth factor receptor (VEGFR) tyrosine kinase inhibitor (TKI). The trial aims to establish a safe, tolerable, and effi...
What is the current status of trial NCT04777994?
This trial is currently recruiting. It is a Phase 1 study. The enrollment target is 248 participants. The study started on 2021-03-09. Estimated completion is 2026-10.
What conditions does trial NCT04777994 study?
This clinical trial studies the following conditions: Advanced Solid Tumor Cancer.
What interventions are being tested in trial NCT04777994?
The interventions under investigation include: ABBV-CLS-484 (DRUG), Vascular Endothelial Growth Factor Receptor (VEGFR) Tyrosine Kinase Inhibitor (TKI) (DRUG), Programmed Cell Death-1 (PD-1) Inhibitor (DRUG).
Who is sponsoring clinical trial NCT04777994?
This trial is sponsored by Calico Life Sciences, which has 6 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT04777994 being conducted?
This trial has 20 study locations across Arizona, Connecticut, Maryland, Massachusetts, Michigan. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Advanced Solid Tumor Cancer
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.